<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654157</url>
  </required_header>
  <id_info>
    <org_study_id>D1843R00279</org_study_id>
    <nct_id>NCT03654157</nct_id>
  </id_info>
  <brief_title>ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow</brief_title>
  <official_title>A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Cardiovascular diseases (CVD) are currently the leading cause of death in industrialized
      countries and are expected to become the leading cause of death in emerging countries by
      20201. According to the official Russian statistics, in 2015, CVD was the cause in 34% of
      deaths in Russia2.

      Acute Coronary Syndrome (ACS) is the most prevalent manifestation of CVD and is associated
      with high mortality and morbidity. No other life-threatening disease is as prevalent or
      expensive to society3. In 2014 in Russian Federation 46 250 people died from acute myocardial
      infarction (MI) and 17 605 people died from recurrent MI4.

      ACS is a clinical syndrome characterized by unstable angina (UA), non-ST-segment elevation
      myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). The
      most common cause of ACS is reduced myocardial perfusion that results from coronary artery
      narrowing caused by the formation of partially or totally occlusive thrombi in response to
      rupture of atherosclerotic plaques on the vessel wall5-7.

      In Russian Federation ACS management after ACS is provided in out-patient settings by doctors
      of different specialties (cardiologists and general practitioners (GPs)). However, the
      management of ACS in out-patient settings in some regions in Russian Federation is frequently
      suboptimal. Moscow city significantly differs from other parts of Russia from ACS management
      at hospital stage (up to 90% of PCI managed ST elevation myocardial infarction (MI) patients,
      no thrombolysis, short first medical contact to balloon time etc.) but it is unclear if
      management of post MI patients in Moscow out-patient settings is also optimal. In-hospital
      mortality in MI patients decreased last years but there is no data on clinical outcomes
      during 12 months after MI in Moscow.

      This study will provide the epidemiological data about rates of major adverse cardiovascular
      and cerebrovascular events (MACCE) (MI, stroke, cardiovascular death) within 12 months after
      MI in real clinical practice in Moscow and describe DAPT at out-patient setting. The
      information received in this study will help to optimize management of Russian patients with
      ACS. The data will be used in discussion with payers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the cumulative incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACСE)</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objective of this study is to describe the cumulative incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACСE) [MI, stroke, and cardiovascular death] observed over 1 year after index MI in all patients enrolled in the study.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Heart Attack</condition>
  <condition>Stroke</condition>
  <condition>Cardiovascular Death</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients who survived myocardial infarction and who come for further
        treatment and observation to polyclinic after discharge from hospital will be enrolled in
        this study if a patient provides a consent form. It is estimated that at least 2500 post MI
        patients are to be enrolled in the study. It is also assumed that the total size of the
        study population could be up to 10 000 post MI patients who are observed in polyclinics of
        Moscow city within first year after index event.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subject population that will be observed in this prospective study must meet the
        following criteria:

          1. Patients survivors who visited outpatient setting after discharge from hospital due to
             MI (STEMI or NSTEMI) within 1 month after discharge from hospital;

          2. Obtained written informed consent for participation in this study.

          3. Age of 18 year or older.

        Exclusion Criteria:

          1. Current participation in a clinical study.

          2. Unknown type of MI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Pesheva</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 121 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatyana Yurchak</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 52 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Veronika Vovk</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 2 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitriy Privalov</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GKB # 51 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Klepikova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GKB # 13 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Belkorey</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 218 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalya Karabinskaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 19 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalya Bosyakova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 19 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Lepatova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 107 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Dorofeeva</last_name>
    <role>Principal Investigator</role>
    <affiliation>FGBU &quot;Polyclinic # 1&quot; Administrative Department of the President of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irina Shoshina</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 109 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darya Semenova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 23 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Zherebetskaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ KDC # 2 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Yarygina</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 175 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Lukinskaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 115 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irina Borovikova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 209 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Sladkova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 22 DZM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Demyanova</last_name>
    <role>Principal Investigator</role>
    <affiliation>GBUZ GP # 64 DZM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olga Pesheva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tatyana Yurchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veronika Vovk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dmitriy Privalov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Klepikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olga Belkorey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natalya Karabinskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Lepatova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Dorofeeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irina Shoshina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Darya Semenova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Zherebetskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Yarygina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Lukinskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irina Borovikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tatiana Sladkova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Demyanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>D1843r00279</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000 Mar;83(3):361-6. Review.</citation>
    <PMID>10677422</PMID>
  </reference>
  <reference>
    <citation>Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 Jul;28(13):1598-660. Epub 2007 Jun 14.</citation>
    <PMID>17569677</PMID>
  </reference>
  <reference>
    <citation>Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000 Sep;36(3):970-1062. Erratum in: J Am Coll Cardiol 2001 Jul;38(1):294-5.</citation>
    <PMID>10987629</PMID>
  </reference>
  <reference>
    <citation>Vasilyeva EY, Plavunov NF, Kalinskaya AI, Sapina AI, Vvedensky GA, Lebedeva AY, Skrypnyk DV, Shpektor AV. [Treatment of Patients With Acute Myocardial Infarction With ST-Segment Elevation. Organization of the Myocardial Infarction Network in Moscow]. Kardiologiia. 2016 Dec;56(12):48-53. Russian.</citation>
    <PMID>28290804</PMID>
  </reference>
  <reference>
    <citation>Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015 May 14;36(19):1163-70. doi: 10.1093/eurheartj/ehu505. Epub 2015 Jan 13.</citation>
    <PMID>25586123</PMID>
  </reference>
  <reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </reference>
  <reference>
    <citation>Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015 Jul 28;66(4):403-69. doi: 10.1016/j.jacc.2014.12.018. Epub 2014 Dec 29. Erratum in: J Am Coll Cardiol. 2015 Aug 25;66(8):982.</citation>
    <PMID>25553722</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

